A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
